Enzymotec Ltd (ENZY) 7.30 $ENZY Should You Get Rid of

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 11:19 AM

Enzymotec Ltd (ENZY) 7.30 $ENZY

Should You Get Rid of Enzymotec (ENZY) Now?
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:42AM CDT
Enzymotec (ENZY) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.
ENZY: 7.30 (-0.07)

Enzymotec Ltd. Reports Second Quarter 2016 Unaudited Financial Results
GlobeNewswire - Tue Aug 09, 6:30AM CDT
VAYA Pharma Generated Record Net Revenues of $3.4 Million
ENZY: 7.30 (-0.07)

Enzymotec Ltd. To Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue Aug 02, 7:30AM CDT
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that Dr. Ariel Katz, the Company's Chief Executive Officer, is scheduled to present at the Jefferies Industrial Conference, being held August 9 - 11, 2016 in New York City and the Canaccord Genuity Annual Growth Conference, being held August 10 - 11, 2016 in Boston.
ENZY: 7.30 (-0.07)

Enzymotec Ltd. Reports First Quarter 2016 Unaudited Financial Results
GlobeNewswire - Thu May 19, 6:30AM CDT
Reports Net Revenues of $14.0 Million, Earns $0.09 Per Diluted Share (non-GAAP) and Generates $3.3 Million in Operating Cash Flow
ENZY: 7.30 (-0.07)

Enzymotec to Report First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 7:30AM CDT
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that the Company will release financial results for the first quarter ended March 31, 2016 on Thursday, May 19, 2016, before the market opens. Following the release, Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review the financial results.
ENZY: 7.30 (-0.07)

Update to Enzymotec Ltd. Shareholders Regarding Securities Class Action Lawsuit
Marketwired - Fri Apr 08, 3:05PM CDT
Co-Lead Counsel in the securities class action lawsuit pending in the District of New Jersey, which was filed in September 2014, provide this update to purchasers of Enzymotec Ltd.'s ("Enzymotec"

common stock during the Class Period between September 27, 2013 and August 4, 2014, inclusive, and also to purchasers of Enzymotec shares pursuant and/or traceable to the Company's initial public offering of its common stock (the "IPO"

on or about September 27, 2013 and the Company's secondary public offering ("SPO"

on or about February 27, 2014.
ENZY: 7.30 (-0.07)

Enzymotec Ltd. Granted Patents in U.S. for Compositions and Processes Related to Infant Nutrition and China for INFAT(R) Uses Promoting Development of Beneficial Gut Flora and Reducing Infant Crying Duration
GlobeNewswire - Tue Mar 29, 7:30AM CDT
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that the Company has been granted two patents, one by the United States Patent Office and the second by the Chinese Patent and Trademark Office.
ENZY: 7.30 (-0.07)

Enzymotec Announces Positive Outcome in ICC Arbitration Award
GlobeNewswire - Tue Feb 02, 7:30AM CST
Arbitration tribunal rejects AAK's requests for declaratory relief in their entirety
ENZY: 7.30 (-0.07)

Enzymotec Updates Automatic Extension of Its Joint Venture Agreement With AAK Until December 31, 2019
GlobeNewswire - Mon Jan 04, 7:00AM CST
Enzymotec Ltd. (NASDAQ:ENZY) (the "Company"

, a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, reports that neither it nor AarhusKarlshamn AB, or AAK, a Sweden-based, global producer of specialty oils that is Enzymotec's joint venture partner in Advanced Lipids AB, has issued a notice of termination of the joint venture agreement (the "JV Agreement"

to the other party by the December 31, 2015 deadline that is specified under the terms of the JV Agreement. Hence, under its terms, the JV Agreement has been automatically extended until December 31, 2019.
ENZY: 7.30 (-0.07)

Enzymotec Granted Mexican Patent for INFAT(R) Uses Related to Promoting Intestinal Health
GlobeNewswire - Mon Dec 21, 7:30AM CST
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that INFAT(R), the innovative ingredient that is marketed by Advanced Lipids, an AAK and Enzymotec joint venture, was granted a patent by the Mexican Patent Office for uses related to promoting intestinal health.
ENZY: 7.30 (-0.07)

Enzymotec's InCog(TM), an Innovative Lipid Composition for Cognitive Functioning, Approved as Novel Food in Europe
GlobeNewswire - Tue Dec 01, 7:30AM CST
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that its InCog, an innovative lipid composition for cognitive functioning, received Novel Food approval in Europe for conventional food, food supplements and dietary food for special medical purposes.
ENZY: 7.30 (-0.07)

Why Enzymotec (ENZY) Could Be Positioned for a Surge?
Zacks Equity Research - Zacks Investment Research - Mon Nov 23, 7:58AM CST
Enzymotec is seeing solid activity on the earnings estimate revision front, and the stock has also started to move higher lately, adding 14.7% over the past four weeks
ENZY: 7.30 (-0.07)

Enzymotec Ltd. Reports Third Quarter 2015 Results
GlobeNewswire - Wed Nov 11, 6:30AM CST
Earns non-GAAP $0.08 and GAAP $0.07 per Diluted Share and Generates $4.7 Million in Operating Cash Flow
ENZY: 7.30 (-0.07)

Enzymotec to Host a VAYA Pharma Analyst and Investor Day in New York City on November 19, 2015
GlobeNewswire - Tue Nov 10, 7:30AM CST
Enzymotec Ltd. (NASDAQ:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, today announced that the Company will host a VAYA Pharma Analyst and Investor Day at Four Times Square in New York City on November 19, 2015, beginning at 12pm ET.
ENZY: 7.30 (-0.07)

Retrospective Analysis of the Effects of Enzymotec's Vayarin(R) Showed Significant Improvement of Emotional Status and Sleep Quality in ADHD Patients With Sleep Disturbances
GlobeNewswire - Mon Nov 09, 8:00AM CST
Enzymotec Ltd. (Nasdaq:ENZY) ("Enyzmotec" or the "Company"

, a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, today announced that a poster entitled "ANALYZING THE EFFECT OF VAYARIN(R) ON EMOTIONAL REGULATION AND SLEEP QUALITY IN ADHD PATIENTS SUFFERING FROM SLEEP DISTURBANCES" was presented at the American Academy of Child and Adolescent Psychiatry's (AACAP) 62nd annual meeting by Dr. Arnold Mech, Medical Director and Head of The Mech Center Outpatient and Research, Sleep Centers of Texas. The poster presentation outlined the results of a retrospective analysis that evaluated the effect of Vayarin(R) on emotional regulation and sleep quality in ADHD patients suffering from sleep disturbances.
ENZY: 7.30 (-0.07)

Enzymotec to Report Third Quarter 2015 Financial Results
GlobeNewswire - Wed Oct 28, 3:05PM CDT
Enzymotec Ltd. (NASDAQ:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today announced that the Company will release financial results for the third quarter ended September 30, 2015 on Wednesday, November 11, 2015, before the market opens. Following the release, Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review the financial results.
ENZY: 7.30 (-0.07)

Enzymotec Ltd. Granted a New US Patent for Vayacog(R) in Pre-Dementia
GlobeNewswire - Wed Oct 28, 7:30AM CDT
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today it was granted a new patent by the United States Patent and Trademark Office for Vayacog(R), a proprietary prescription medical food for the dietary management of lipid imbalances associated with early memory impairment.
ENZY: 7.30 (-0.07)

Medtronic Next-Gen superDimension System to Aid Lung Cancer
Zacks Equity Research - Zacks Investment Research - Mon Oct 12, 1:20PM CDT
Medtronic's (MDT) superDimension navigation system is used in conjunction with GenCut core biopsy system to detect lung cancer, using the minimally invasive ENB approach.
ICUI: 123.70 (-1.07), MDT: 86.42 (-0.61), ENZY: 7.30 (-0.07), NUVA: 64.90 (-0.57)

Cardiovascular Systems Down on Bleak Q1 Preliminary Results
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:15PM CDT
Cardiovascular Systems' (CSII) preliminary fiscal first quarter results fell short of the Zacks Consensus Estimate on both the top and bottom-line fronts.
ICUI: 123.70 (-1.07), CSII: 24.28 (-0.19), ENZY: 7.30 (-0.07), NUVA: 64.90 (-0.57)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Geron Corp Faces Fiduciary Duty Investigation

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

CVS Health Under Fire: Fiduciary Duty Breach?

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

AI and Storytelling Make Waves in Science Education

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...